Market Overview

Analyst: Ford's Turnaround Still Stuck In Neutral

Share:
Analyst: Ford's Turnaround Still Stuck In Neutral
Related F
Trump Threatens European Auto Tariffs, But May Have Himself To Blame For Record Trade Deficit
Bulls & Bears Of The Week: Apple, Disney, Ford, Target And More
10 Of 59 Consumer Cyclical 'Safer' Dividend WallStars Flash 25.6%-50.8% Gains Per Broker November Targets (Seeking Alpha)

RBC Capital Markets watches the auto race from the sidelines.

The research firm has a Hold on General Motors Company (NYSE: GM), the most likeable automaker on the Street, and a Hold on Tesla Inc (NASDAQ: TSLA), which some consider the industry frontrunner.

On Monday, it slapped the same rating on Ford Motor Company (NYSE: F).

“Net, while we believe new CEO Jim Hackett has a solid long-term vision, it is very early in the turnaround and we think little can change over the coming years (making F subject to cycle),” analyst Joseph Spak said in a note. RBC downgraded Ford to Perform with a $13 price target.

Following The Leader

The earlier Outperform rating built on poor Street expectations, relatively attractive production rates, and the potential to profit from a border-adjusted tax.

While the tax reform has yet to actualize, Hackett’s appointment bolstered RBC’s turnaround thesis. The CEO committed to shaving $14 billion in materials and engineering, refocusing Ford on its profitable units, emphasizing higher-priced cars at lower volumes and shifting $7 billion from cars to trucks and utility vehicles.

“We believe these are the right steps, but they also don’t necessarily differentiate Ford from what other OEMs are doing,” Spak wrote. “Ford’s ideas on connected vehicles and services in the future of mobility are interesting but very high-level. More specifics and a flush-out of the ideas are needed.”

He expects not to see material impact from Hackett’s efforts until 2019 or 2020.

Cruising The Street

RBC predicts third-quarter earnings per share of $0.30 against the Street’s $0.32 and, considering no production of Navigators or Expeditions, models for a slight year-over-year decrease in North American pre-tax profit.

“We believe 2H17 appears healthy, with expectations appropriately set, with a possible tailwind from strong replacement demand from hurricane-impacted areas,” Spak wrote.

Despite “attractive” valuation and dividend yield, he considers 2018 EPS estimates about 8 percent too high driven by undue optimism in pre-tax margin recovery.

At time of publication, Ford was trading at $12.09.

Related Links:

Has GM Finally Taken The Lead In Autonomous Vehicles?

Auto Sales Ramp Up In September Buoyed By Labor Day Boost

Latest Ratings for F

DateFirmActionFromTo
Oct 2018NomuraMaintainsNeutralNeutral
Oct 2018Goldman SachsUpgradesNeutralBuy
Oct 2018BuckinghamMaintainsNeutralNeutral

View More Analyst Ratings for F
View the Latest Analyst Ratings

Posted-In: Joseph Spak RBC CapitalAnalyst Color Downgrades Price Target Travel Analyst Ratings General Best of Benzinga

 

Related Articles (F + GM)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
LXFTKeyBancDowngrades0.0
CPAImperial CapitalDowngrades68.0
PRMWImperial CapitalInitiates Coverage On18.0
TGTKeyBancInitiates Coverage On110.0
QCOMMorgan StanleyUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mid-Afternoon Market Update: Sears Tumbles After Bruce Berkowitz Resigns From Board; Exelixis Shares Surge

4 Biotechs Boosted By Spark Therapeutic's FDA News